CLRB vs. PRLD, RNTX, KALA, CNTB, CELU, XLO, DYAI, ALVR, ATRA, and OSTX
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Prelude Therapeutics (PRLD), Rein Therapeutics (RNTX), KALA BIO (KALA), Connect Biopharma (CNTB), Celularity (CELU), Xilio Therapeutics (XLO), Dyadic International (DYAI), AlloVir (ALVR), Atara Biotherapeutics (ATRA), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs.
Prelude Therapeutics (NASDAQ:PRLD) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 62.8% of Prelude Therapeutics shares are owned by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cellectar Biosciences' return on equity of 0.00% beat Prelude Therapeutics' return on equity.
Cellectar Biosciences has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Prelude Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Prelude Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 359.29%. Cellectar Biosciences has a consensus price target of $17.67, indicating a potential upside of 5,526.33%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Prelude Therapeutics.
In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 1 articles in the media. Prelude Therapeutics' average media sentiment score of 0.00 equaled Cellectar Biosciences'average media sentiment score.
Cellectar Biosciences received 213 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 54.85% of users gave Cellectar Biosciences an outperform vote while only 49.18% of users gave Prelude Therapeutics an outperform vote.
Summary
Cellectar Biosciences beats Prelude Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CLRB Stock Alerts